Literature DB >> 19299008

Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy.

Yu-Hsin Lin1, Chiung-Hung Chang, Yu-Shiun Wu, Yuan-Man Hsu, Shu-Fen Chiou, Yi-Jen Chen.   

Abstract

The microorganism now known as Helicobacter pylori is considered to be an important factor in the etiology of peptic ulcers. It can secrete urease enzyme and buffer gastric acids to survive in the stomach. H. pylori can colonize the gastric mucosa and preferentially adheres near the cell-cell junctions of the gastric mucous cells. In this study, pH-responsive nanoparticles were produced instantaneously upon the addition of heparin solution to a chitosan solution with magnetic stirring at room temperature. The nanoparticles appeared to have a particle size of 130-300 nm, with a positive surface charge, and were stable at pH 1.2-2.5, allowing them to protect an incorporated drug from destructive gastric acids. We also demonstrated that the prepared nanoparticles can adhere to and infiltrate cell-cell junctions and interact locally with H. pylori infection sites in intercellular spaces.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299008     DOI: 10.1016/j.biomaterials.2009.02.036

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  24 in total

Review 1.  Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents.

Authors:  Anumita Chaudhury; Surajit Das
Journal:  AAPS PharmSciTech       Date:  2010-12-11       Impact factor: 3.246

Review 2.  Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting.

Authors:  Muhammad Abdur Rahim; Nasrullah Jan; Safiullah Khan; Hassan Shah; Asadullah Madni; Arshad Khan; Abdul Jabar; Shahzeb Khan; Abdelbary Elhissi; Zahid Hussain; Heather C Aziz; Muhammad Sohail; Mirazam Khan; Hnin Ei Thu
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

3.  Concurrent Delivery of Soluble and Immobilized Proteins to Recruit and Differentiate Neural Stem Cells.

Authors:  Trevor R Ham; Dakotah G Cox; Nic D Leipzig
Journal:  Biomacromolecules       Date:  2019-08-28       Impact factor: 6.988

Review 4.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

Review 5.  pH-Responsive nanoparticles for drug delivery.

Authors:  Weiwei Gao; Juliana M Chan; Omid C Farokhzad
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

Review 6.  Exploiting the tumor microenvironment for theranostic imaging.

Authors:  Ioannis Stasinopoulos; Marie-France Penet; Zhihang Chen; Samata Kakkad; Kristine Glunde; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2011-01-28       Impact factor: 4.044

7.  Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection.

Authors:  Pavimol Angsantikul; Soracha Thamphiwatana; Qiangzhe Zhang; Kevin Spiekermann; Jia Zhuang; Ronnie H Fang; Weiwei Gao; Marygorret Obonyo; Liangfang Zhang
Journal:  Adv Ther (Weinh)       Date:  2018-05-08

8.  In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation.

Authors:  Soracha Thamphiwatana; Weiwei Gao; Marygorret Obonyo; Liangfang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

9.  Serratiopeptidase loaded chitosan nanoparticles by polyelectrolyte complexation: in vitro and in vivo evaluation.

Authors:  Nitin Mali; Preeti Wavikar; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2014-08-30       Impact factor: 3.246

10.  Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery.

Authors:  Soracha Thamphiwatana; Victoria Fu; Jingying Zhu; Diannan Lu; Weiwei Gao; Liangfang Zhang
Journal:  Langmuir       Date:  2013-09-16       Impact factor: 3.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.